Response to letter entitled: Re: Can we replace adjuvant chemotherapy with surveillance for stage IA-C immature ovarian teratomas of any grade? An international multicenter analysis
1 Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy; Università Vita Salute San Raffaele, Milan, Italy. Electronic address: bergamini.alice@hsr.it.
2 Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College London, London, UK.
3 Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, Istituto di Ginecologia e Ostetricia, Roma, Italy.
4 Department of Obstetrics, Gynecology and Neonatology, University of Milan, Ospedale Maggiore Policlinico, Milan, Italy.
5 Department of Obstetrics and Gynecology, IRCCS Foundation Policlinico San Matteo, Pavia, Italy.
6 Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, UK.
7 Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" Bari & Department of Biomedical Sciences and Human Oncology, University of Bari, UK.
8 Department of Imaging, Charing Charing Cross Hospital Campus of Imperial College London, London, UK.
9 Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80138 Naples, Italy.
10 Department of Obstetrics and Gynecology, IRCCS San Raffaele Hospital, Milan, Italy.
11 Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College London, London, UK. Electronic address: m.seckl@imperial.ac.uk.